News | Pleins feux sur la technologie ARN | La Presse

A recent article in La Presse, , highlights how Quebec's life sciences sector is experiencing a significant revival with the creation of an RNA hub.
Here is a exerpt from the article (translated to english):Ìę
âThere's an incredible amount of excitement.â That's how Claude LeDuc, CEO of RNA Technologies & Therapeutics (RNA T & T), sums up the climate in Montreal's life sciences and health technology sector.
His company, which specializes in the design, optimization and small- to medium-scale production of RNA, as well as the development of messenger RNA (mRNA)-based therapeutics, has had a flawless track record since its launch in July 2022.
It's extraordinary,â admits Claude LeDuc. Within a month of our existence, we had found a laboratory in Laval and started our RNA commercialization activities. Within the first few months, we had generated enough funds to be financially self-sufficient.â
Without giving any figures, he adds that the 10-employee company raked in âsignificant surplusesâ in its first financial year. âThat enabled us to buy $1 million worth of equipment, with the support of government programs. We managed to quintuple the capacity of certain stages of our production. We're still growing. We want to become a center of RNA production for personalized medicine.â
In June, RNA T & T moved its headquarters to the Institut de recherches cliniques de Montréal (IRCM). The company is currently working on three research projects with the IRCM, to test the efficacy of innovative approaches to treating leukemia, cancer and diabetes.
Frank BĂ©raud, President and CEO of MontrĂ©al InVivo, notes that QuĂ©bec - and MontrĂ©al in particular - has âvery strong expertiseâ in RNA. âIt's a niche of excellence that's developing,â he says. The launch of AReNa, the province's RNA hub, has mobilized players in the sector. The first projects selected for funding will be unveiled in the coming days.
Claude LeDuc believes that the investments announced, including the $20 million over two years to make Quebec an innovation hub, will âaccelerate the development of RNA therapiesâ.
Ìę